过氧化物酶体增殖物激活受体4作为早期肺鳞状细胞癌患者生存的独立预后标志物。
Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
作者信息
Hwang Ji An, Song Joon Seon, Yu Dae Yeul, Kim Hyeong Ryul, Park Hye Jin, Park Young Soo, Kim Woo Sung, Choi Chang Min
机构信息
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea.
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea.
出版信息
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6627-35. eCollection 2015.
OBJECTIVES
Peroxiredoxin 4 (Prx 4) is a newly emerging antioxidant protein that has been studied in several human cancers. Recently, it was revealed that Prx 4 is highly expressed in human lung cancer and is needed for the promotion of lung cancer progression in vitro. However, there are no clinical data regarding the association of Prx 4 and prognosis in lung cancer.
MATERIALS AND METHODS
The Prx 4 expression state as a prognostic indicator was assessed by immunohistochemical staining in 142 patients with stage II non-small cell lung cancer (NSCLC) who had undergone curative surgery between 2006 and 2010. The association between the degree of Prx 4 expression and several clinicopathologic parameters was then evaluated by statistical analyses.
RESULTS
The degree of Prx 4 expression was associated with histology and recurrence in the overall NSCLC patient group, with the proportion of patients with positive Prx 4 expression significantly higher for the adenocarcinoma subtype (39/70, 56%) than the squamous cell carcinoma subtype (23/72, 32%) (P = 0.004). However, when subgroup analyses according to histopathology were performed in terms of recurrence, positive Prx 4 expression was significantly correlated with higher recurrence rates (P = 0.003) and shorter disease-free survival (DFS) (P = 0.003, hazard ratio = 3.910) in patients with squamous cell carcinoma. In contrast, no meaningful relationship was observed between the level of Prx 4 expression and DFS in the adenocarcinoma subgroup.
CONCLUSION
Positive Prx 4 expression is significantly correlated with recurrence and shorter DFS in patients with early-stage lung squamous cell carcinoma.
目的
过氧化物酶体增殖物激活受体4（Prx 4）是一种新出现的抗氧化蛋白，已在多种人类癌症中得到研究。最近发现，Prx 4在人类肺癌中高表达，并且在体外促进肺癌进展中是必需的。然而，关于Prx 4与肺癌预后的相关性尚无临床数据。
材料与方法
通过免疫组织化学染色评估了2006年至2010年间接受根治性手术的142例II期非小细胞肺癌（NSCLC）患者中Prx 4表达状态作为预后指标的情况。然后通过统计分析评估Prx 4表达程度与几种临床病理参数之间的相关性。
结果
在整个NSCLC患者组中，Prx 4表达程度与组织学和复发相关，腺癌亚型中Prx 4表达阳性患者的比例（39/70，56%）显著高于鳞状细胞癌亚型（23/72，32%）（P = 0.004）。然而，在根据组织病理学进行复发亚组分析时，Prx 4表达阳性与鳞状细胞癌患者的较高复发率（P = 0.003）和较短无病生存期（DFS）（P = 0.003，风险比 = 3.910）显著相关。相比之下，在腺癌亚组中未观察到Prx 4表达水平与DFS之间有意义的关系。
结论
Prx 4表达阳性与早期肺鳞状细胞癌患者的复发和较短DFS显著相关。
Zotero 插件